Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Apr 20, 2010


Alexis Borisy is the founding CEO of Foundation Medicine, a Cambridge, Mass.-based startup that aims to bring comprehensive cancer genome analysis into the clinic and to develop clinical laboratory tests using next-generation sequencing and other technologies. The company recently raised $25 million in a Series A funding round led by Third Rock Ventures.

The firm's academic advisors include Eric Lander, director of the Broad Institute, professor of biology at the Massachusetts Institute of Technology, and professor of systems biology at Harvard Medical School; Todd Golub, director of the Broad Institute's cancer program, an investigator in human cancer genetics at the Dana-Farber Cancer Institute and professor of pediatrics at Harvard Medical School; Levi Garraway, an assistant professor of medicine in the Department of Medical Oncology at Dana-Farber; and Matthew Meyerson, director of the Center for Cancer Genome Discovery at Dana-Farber and a professor of pathology at Harvard Medical School.

The firm's board of directors includes CEO Alexis Borisy; Mark Levin, a partner at investor Third Rock Ventures and former CEO of Millennium Pharmaceuticals; David Schenkein, CEO of Agios Pharmaceuticals and former leader of Genentech’s BioOncology development portfolio; and Robert Tepper, a partner at Third Rock Ventures and former president of research and development at Millennium.

Duncan Whitney has joined Allegro Diagnostics as vice president for research and development. Previously, he held executive-level scientific roles at Exact Sciences, US Genomics, and Progenika. Whitney holds PhD and master's degrees in chemistry from the Massachusetts Institute of Technology and a BS in chemistry from Colby College.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.